EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Mari I Suominen iD, Matias Knuuttila iD, Christoph A Schatz iD, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler iD, Dominik Mumberg iD, Sanna-Maria Käkönen iD, Arne Scholz

International Journal of Molecular Sciences · 22.01.2023 · 24 (3) · 2189

DOI: 10.3390/ijms24032189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.01.2023. Verfasst von Mari I Suominen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmatest Services Ltd., 20520 Turku, Finland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor efficacy of radium-223, enzalutamide, and their combination in the intratibial LNCaP model mimicking prostate cancer metastasized to bone. In vitro experiments revealed that the combination of radium-223 and enzalutamide inhibited LNCaP cell proliferation and showed synergistic efficacy. The combination of radium-223 and enzalutamide also demonstrated enhanced in vivo antitumor efficacy, as determined by measuring serum PSA levels in the intratibial LNCaP model. A decreasing trend in the total area of tumor-induced abnormal bone was associated with the combination treatment. The serum levels of the bone formation marker PINP and the bone resorption marker CTX-I were lowest in the combination treatment group and markedly decreased compared with vehicle group. Concurrent administration of enzalutamide did not impair radium-223 uptake in tumor-bearing bone or the ability of radium-223 to inhibit tumor-induced abnormal bone formation. In conclusion, combination treatment with radium-223 and enzalutamide demonstrated enhanced antitumor efficacy without compromising the integrity of healthy bone. The results support the ongoing phase 3 trial of this combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiumBone NeoplasmsMaleHumansPhenylthiohydantoinBenzamidesNitriles

Stichwörter der Autor:innen

CRPCbone metastasesenzalutamideprostate cancerradium-223targeted alpha therapy

Substanzen

Radium-223enzalutamidePhenylthiohydantoinRadiumBenzamidesNitriles

Autor:innen und Institutionen

  • Pharmatest Services Ltd., 20520 Turku, Finland.
  • Aurexel Life Sciences Ltd., 21240 Askainen, Finland.
  • Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Inoi Oy, 20100 Turku, Finland.
  • Institute of Biomedicine, University of Turku, 20520 Turku, Finland.

ORCID-Profile: Mari I Suominen, Matias Knuuttila, Christoph A Schatz, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen

Förderung

  • Bayer AG

Zitieren

APA

Suominen, M. I., Knuuttila, M., Schatz, C. A., Schlicker, A., Vääräniemi, J., Sjöholm, B., Alhoniemi, E., Haendler, B., Mumberg, D., Käkönen, S. M., & Scholz, A. (2023). Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International Journal of Molecular Sciences, 24(3), 2189. https://doi.org/10.3390/ijms24032189

Vancouver

Suominen MI, Knuuttila M, Schatz CA, Schlicker A, Vääräniemi J, Sjöholm B, et al. Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International Journal of Molecular Sciences. 2023;24(3):2189. doi:10.3390/ijms24032189

BibTeX
@article{Suominen2023,
  author = {Suominen, Mari I and Knuuttila, Matias and Schatz, Christoph A and Schlicker, Andreas and Vääräniemi, Jukka and Sjöholm, Birgitta and Alhoniemi, Esa and Haendler, Bernard and Mumberg, Dominik and Käkönen, Sanna-Maria and Scholz, Arne},
  title = {Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2189},
  doi = {10.3390/ijms24032189}
}
Kostenlos starten →